110 related articles for article (PubMed ID: 10493618)
1. Post-perfusion recurrent melanoma.
Polk HC; Edwards MJ
Ann Surg Oncol; 1999 Sep; 6(6):524. PubMed ID: 10493618
[No Abstract] [Full Text] [Related]
2. Results of regional hyperthermic perfusion for primary and recurrent melanomas of the extremities.
Jönsson PE; Hafström L; Hugander A
Recent Results Cancer Res; 1983; 86():277-82. PubMed ID: 6648009
[No Abstract] [Full Text] [Related]
3. Local and regional therapies for melanoma: many arrows in the quiver.
Thompson JF
J Surg Oncol; 2014 Mar; 109(4):295. PubMed ID: 24419862
[No Abstract] [Full Text] [Related]
4. [Locoregional recurrence of melanomas of the extremities after hyperthermic extremity perfusion: is reperfusion of value?].
Meyer T; Göhl J; Hohenberger W
Langenbecks Arch Chir Suppl Kongressbd; 1998; 115():1452-4. PubMed ID: 9931909
[TBL] [Abstract][Full Text] [Related]
5. Regional therapies for in-transit disease.
Speicher PJ; Meriwether CH; Tyler DS
Surg Oncol Clin N Am; 2015 Apr; 24(2):309-22. PubMed ID: 25769714
[TBL] [Abstract][Full Text] [Related]
6. Treatment of melanoma in-transit metastases confined to the limb.
Eggermont AM
Cancer Surv; 1996; 26():335-49. PubMed ID: 8783582
[No Abstract] [Full Text] [Related]
7. Repeat isolated limb perfusion with TNFalpha and melphalan for recurrent limb melanoma after failure of previous perfusion.
Noorda EM; Vrouenraets BC; Nieweg OE; van Geel AN; Eggermont AM; Kroon BB
Eur J Surg Oncol; 2006 Apr; 32(3):318-24. PubMed ID: 16412605
[TBL] [Abstract][Full Text] [Related]
8. Improved survival of patients with stage II melanoma of the extremity using hyperthermic isolation perfusion with 1-phenylalanine mustard.
Hartley JW; Fletcher WS
J Surg Oncol; 1987 Nov; 36(3):170-4. PubMed ID: 3682836
[TBL] [Abstract][Full Text] [Related]
9. Toxicity of hyperthermic isolated limb perfusion with cisplatin for recurrent melanoma of the lower extremity after previous perfusion treatment.
Hoekstra HJ; Schraffordt Koops H; de Vries LG; van Weerden TW; Oldhoff J
Cancer; 1993 Aug; 72(4):1224-9. PubMed ID: 8393368
[TBL] [Abstract][Full Text] [Related]
10. [Isolated hyperthermic perfusion of extremities in malignant melanoma with melphalan and tumor necrosis factor].
Kettelhack C; Hohenberger P; Schlag PM
Langenbecks Arch Chir Suppl Kongressbd; 1996; 113():127-9. PubMed ID: 9101810
[TBL] [Abstract][Full Text] [Related]
11. Regional perfusion for melanoma: was it worth the bother?
Cox KR; Ewing M
Br J Surg; 1969 Aug; 56(8):615. PubMed ID: 5797732
[No Abstract] [Full Text] [Related]
12. Regional hyperthermic perfusion with melphalan after surgery for recurrent malignant melanoma of the extremities--long-term follow-up of a randomised trial.
Olofsson Bagge R; Mattsson J; Hafström L
Int J Hyperthermia; 2014 Aug; 30(5):295-8. PubMed ID: 25144818
[TBL] [Abstract][Full Text] [Related]
13. Current management of malignant melanoma.
Coit DG; Brennan MF
Surgery; 1993 Feb; 113(2):128-9. PubMed ID: 8430360
[No Abstract] [Full Text] [Related]
14. Recurrent cutaneous melanoma: a surgical perspective.
Yeung RS
Semin Oncol; 1993 Oct; 20(5):400-18. PubMed ID: 8211191
[No Abstract] [Full Text] [Related]
15. Prophylactic hyperthermic limb perfusion in stage I melanoma.
Krige JE; King HS; Strover RM
Eur J Surg Oncol; 1988 Aug; 14(4):321-6. PubMed ID: 3044834
[TBL] [Abstract][Full Text] [Related]
16. Patterns of recurrence following complete response to regional chemotherapy for in-transit melanoma.
Sharma K; Beasley G; Turley R; Raymond AK; Broadwater G; Peterson B; Mosca P; Tyler D
Ann Surg Oncol; 2012 Aug; 19(8):2563-71. PubMed ID: 22476748
[TBL] [Abstract][Full Text] [Related]
17. Hyperthermic perfusion for melanoma of the extremities: experience with 165 patients, 1967 to 1979.
Stehlin JS
Ann N Y Acad Sci; 1980; 335():352-5. PubMed ID: 6931528
[No Abstract] [Full Text] [Related]
18. Isolated hyperthermia chemotherapy perfusion for limb melanoma.
Krementz ET; Sutherland CM; Muchmore JH
Surg Clin North Am; 1996 Dec; 76(6):1313-30. PubMed ID: 8977553
[TBL] [Abstract][Full Text] [Related]
19. [Regional hyperthermic perfusion has impressive effect on manifest malignant melanoma].
Hafström L
Lakartidningen; 1992 Sep; 89(39):3189-90. PubMed ID: 1405932
[No Abstract] [Full Text] [Related]
20. CD30-positive lymphoproliferative disorders arising after regional therapy for recurrent melanoma: a report of two cases and analysis of CD30 expression.
Gill K; Ariyan C; Wang X; Brady MS; Pulitzer M
J Surg Oncol; 2014 Sep; 110(3):258-64. PubMed ID: 24891295
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
